Displaying 1–25 of 52 results for IBM
The partnership aims to explore methods of using patient data and advanced analysis to glean insights on likely breast cancer treatment outcomes.
To realize the promise of the Internet of Things, operational technology systems and information technology systems must converge, allowing connection and communication.
Integration of control and business information technologies are opening new windows of enterprise transparency
Teva Pharmaceutical and IBM Watson Health have announced a strategic partnership whereby Teva will be the first global pharmaceutical company to tap the power of the Watson Health Cloud.
Improving legacy automation systems can present a variety of challenges
If your equipment is not ready, it’s time to get it ready
The sbv IMPROVER project is funded by Philip Morris International and is a collaborative effort between scientists from PMI’s Research and Development department, IBM’s Thomas J. Watson Research Center and, most notably, the entire scientific community.
Want a healthier pharma supply chain? Pave the way with collaboration
Its been 10 years since the FDA released Pharmaceutical GMPs for the 21st Century, but its likely the next 10 that will shape the industry for decades after
Consultant Robert Dream shares thoughts on evolving industries
Digital signatures have grown in sophistication and import, becoming a staple of serious and compliant drug manufacturers, explains SAFE-Biopharma's Mollie Shields-Uehling.
New IDC Health Insights Study Reveals 63% of Pharmaceutical Companies Rely on Third-Party Outsourcing Firms to Enhance Their Manufacturing and Supply Chain Strategies
So much is to be gained, yet it is hard to tell whether any drug manufacturer has truly made progress over the last decade.
Multivariate predictive distribution quantifies the level of QA in a design space. "Parametric bootstrapping" can help simplify early analysis and complement Bayesian methods.
During a legislative lull, drug manufacturers muster up momentum to implement electronic pedigree programs.
By virtualizing its computing, Lilly can do more, with more people involved.
The draft guidance is a win-win-win: good for FDA, consumers, and manufacturers.
Ash Stevens shares information gained from years in the business, and how it will make a new CMC alliance work with various partners.
A just-released IBM study suggests that if life sciences companies do not collaborate, they risk delays in production. The survey, "An Imperfect Harmony: Alliances within the Life Sciences Industry," says that while the number of partnerships between larger and smaller life-sciences companies has...
Eli Lilly and Company has announced that Sidney Taurel, chief executive officer and chairman of the board, will retire as CEO effective March 31, 2008. Taurel will remain chairman of the company's board of directors until December 31, 2008, at which time he will retire from the board and from the...